We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSPH
251
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$548K 0.02%
169,031
+86,414
+105% +$332K
SSKN
252
DELISTED
Strata Skin Sciences
SSKN
$523K 0.02%
9,087
+2,224
+32% +$181K
TSRO
253
CALL
DELISTED
TESARO, Inc.
TSRO
$523K 0.02%
89
-2,529
-97% -$145K
BIOL
254
DELISTED
Biolase, Inc.
BIOL
$522K 0.02%
24
-6
-20% -$146K
LITS
255
Lite Strategy Inc
LITS
$32.4M
$505K 0.02%
14,775
-50
-0.3% -$1.95K
NVO
256
PUT
Novo Nordisk
NVO
$228B
$460K 0.02%
+168
New +$4.72K
XOMA
257
PUT
DELISTED
Xoma
XOMA
$458K 0.02%
+59
New +$4.25K
PGNX
258
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$454K 0.02%
+609
New +$3.68K
PGEN icon
259
PUT
Precigen
PGEN
$1.94B
$439K 0.02%
91
-3
-3% -$126
SKBI
260
DELISTED
SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
$415K 0.02%
156,026
-99,409
-39% -$340K
EXEL icon
261
PUT
Exelixis
EXEL
$13.9B
$381K 0.01%
1,014
+794
+361% +$2.58K
LRMR icon
262
CALL
Larimar Therapeutics
LRMR
$377M
$381K 0.01%
+9
New +$3.77K
CVM.WS
263
DELISTED
Cel-Sci Corp Series S
CVM.WS
$369K 0.01%
1,845,841
-778,534
-30% -$185K
BDSI
264
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$365K 0.01%
458
-2,694
-85% -$23.1K
HTWR
265
CALL
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$363K 0.01%
+50
New +$3.9K
OXGN
266
DELISTED
OXIGENE INC COM
OXGN
$362K 0.01%
+258,435
New +$380K
BLCM
267
CALL
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$342K 0.01%
+16
New +$3.92K
INFI
268
PUT
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$329K 0.01%
300
– –
DYAX
269
CALL
DELISTED
DYAX CORPORATION
DYAX
$326K 0.01%
123
-2,215
-95% -$58.7K
TEVA icon
270
CALL
Teva Pharmaceuticals
TEVA
$40.4B
$319K 0.01%
54
-10,284
-99% -$634K
CYNA
271
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$314K 0.01%
+19,303
New +$317K
IMUX icon
272
PUT
Immunic
IMUX
$178M
– –
0
– –
APDNW
273
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$306K 0.01%
205,347
+19,252
+10% +$21.9K
AGIO icon
274
CALL
Agios Pharmaceuticals
AGIO
$2.08B
$300K 0.01%
27
-216
-89% -$23.3K
RPRX
275
DELISTED
Repros Therapeutics Inc.
RPRX
$298K 0.01%
+41,643
New +$324K
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.